Cargando…

Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer

BACKGROUND: Active surveillance (AS) is recommended by most national medical organizations as the preferred treatment option for men with low-risk prostate cancer (PCa). However, studies report that up to one third of men on AS dropout within 5 years, without evidence of disease progression. Despite...

Descripción completa

Detalles Bibliográficos
Autores principales: Beckmann, Kerri, Cahill, Declan, Brown, Christian, Van Hemelrijck, Mieke, Kinsella, Netty
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261438/
https://www.ncbi.nlm.nih.gov/pubmed/34295758
http://dx.doi.org/10.21037/tau-20-1254
_version_ 1783719013053890560
author Beckmann, Kerri
Cahill, Declan
Brown, Christian
Van Hemelrijck, Mieke
Kinsella, Netty
author_facet Beckmann, Kerri
Cahill, Declan
Brown, Christian
Van Hemelrijck, Mieke
Kinsella, Netty
author_sort Beckmann, Kerri
collection PubMed
description BACKGROUND: Active surveillance (AS) is recommended by most national medical organizations as the preferred treatment option for men with low-risk prostate cancer (PCa). However, studies report that up to one third of men on AS dropout within 5 years, without evidence of disease progression. Despite high dropout rates, few studies have purposively explored the opinions and experiences of men who discontinued AS. The aim of this study was to gain insight into the reasons why some men on AS for PCa discontinue active treatment without evidence of disease progression. METHODS: Semi-structured interviews were undertaken with 14 men from diverse socio-cultural backgrounds who had been on AS for PCa but dropped out of surveillance to undergo active treatment without signs of disease progression. Purposive sampling to reach data saturation was used to select participants based on their experience of AS and willingness to share their experiences. Interviews were transcribed and analysis undertaken in an inductive thematic manner. RESULTS: The following themes arose from interviews as factors that potentially influence adherence to AS: men’s experience at diagnosis and follow-up consultations, involvement in shared decision-making, the extent of supportive care and information, administrative procedures and support from partner and peers. A poor experience during diagnosis could adversely influence long-term adherence to AS, given the same diagnostic tests are frequently repeated. The provision of consistent information and support while on AS, similar to that offered to men undergoing radical treatment, was also highlighted as being important to increase confidence in the process. CONCLUSIONS: Effective communications skills among health professionals, aimed at building trust in patient-clinician relationships, providing opportunities for shared decision-making and developing self-efficacy, along with structured information and support, are key to enhancing long-term adherence to AS.
format Online
Article
Text
id pubmed-8261438
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-82614382021-07-21 Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer Beckmann, Kerri Cahill, Declan Brown, Christian Van Hemelrijck, Mieke Kinsella, Netty Transl Androl Urol Original Article on Expectant Management in Genitourinary Malignancies (Prostate, Bladder, Kidney) BACKGROUND: Active surveillance (AS) is recommended by most national medical organizations as the preferred treatment option for men with low-risk prostate cancer (PCa). However, studies report that up to one third of men on AS dropout within 5 years, without evidence of disease progression. Despite high dropout rates, few studies have purposively explored the opinions and experiences of men who discontinued AS. The aim of this study was to gain insight into the reasons why some men on AS for PCa discontinue active treatment without evidence of disease progression. METHODS: Semi-structured interviews were undertaken with 14 men from diverse socio-cultural backgrounds who had been on AS for PCa but dropped out of surveillance to undergo active treatment without signs of disease progression. Purposive sampling to reach data saturation was used to select participants based on their experience of AS and willingness to share their experiences. Interviews were transcribed and analysis undertaken in an inductive thematic manner. RESULTS: The following themes arose from interviews as factors that potentially influence adherence to AS: men’s experience at diagnosis and follow-up consultations, involvement in shared decision-making, the extent of supportive care and information, administrative procedures and support from partner and peers. A poor experience during diagnosis could adversely influence long-term adherence to AS, given the same diagnostic tests are frequently repeated. The provision of consistent information and support while on AS, similar to that offered to men undergoing radical treatment, was also highlighted as being important to increase confidence in the process. CONCLUSIONS: Effective communications skills among health professionals, aimed at building trust in patient-clinician relationships, providing opportunities for shared decision-making and developing self-efficacy, along with structured information and support, are key to enhancing long-term adherence to AS. AME Publishing Company 2021-06 /pmc/articles/PMC8261438/ /pubmed/34295758 http://dx.doi.org/10.21037/tau-20-1254 Text en 2021 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article on Expectant Management in Genitourinary Malignancies (Prostate, Bladder, Kidney)
Beckmann, Kerri
Cahill, Declan
Brown, Christian
Van Hemelrijck, Mieke
Kinsella, Netty
Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer
title Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer
title_full Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer
title_fullStr Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer
title_full_unstemmed Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer
title_short Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer
title_sort understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer
topic Original Article on Expectant Management in Genitourinary Malignancies (Prostate, Bladder, Kidney)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261438/
https://www.ncbi.nlm.nih.gov/pubmed/34295758
http://dx.doi.org/10.21037/tau-20-1254
work_keys_str_mv AT beckmannkerri understandingreasonsfornonadherencetoactivesurveillanceforlowintermediateriskprostatecancer
AT cahilldeclan understandingreasonsfornonadherencetoactivesurveillanceforlowintermediateriskprostatecancer
AT brownchristian understandingreasonsfornonadherencetoactivesurveillanceforlowintermediateriskprostatecancer
AT vanhemelrijckmieke understandingreasonsfornonadherencetoactivesurveillanceforlowintermediateriskprostatecancer
AT kinsellanetty understandingreasonsfornonadherencetoactivesurveillanceforlowintermediateriskprostatecancer